Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Kyverna Therapeutics, Inc. during its IPO on February 8, 2024, about the lead plaintiff deadline of February 7, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Kyverna common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 7, 2025 [3]. - The lawsuit claims that Kyverna's IPO registration statement and prospectus misrepresented facts regarding the clinical trial results of its lead product candidate, KYV-101, leading to investor damages when the true information was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].
KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTX